BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 29927999)

  • 21. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
    Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
    Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
    Yadav AK; Kumar V; Bailey DB; Jang BC
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.
    Brunen D; García-Barchino MJ; Malani D; Jagalur Basheer N; Lieftink C; Beijersbergen RL; Murumägi A; Porkka K; Wolf M; Zwaan CM; Fornerod M; Kallioniemi O; Martínez-Climent JÁ; Bernards R
    Oncotarget; 2016 Jun; 7(25):37407-37419. PubMed ID: 27270648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors.
    Yun Y; Hong VS; Jeong S; Choo H; Kim S; Lee J
    Chem Pharm Bull (Tokyo); 2021; 69(9):854-861. PubMed ID: 34470949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
    Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
    Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
    Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
    Int J Biol Macromol; 2024 Jun; 270(Pt 1):132030. PubMed ID: 38704069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the Pim kinases in multiple myeloma.
    Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
    Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
    Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
    Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
    Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
    Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β.
    Fan RF; Lu Y; Fang ZG; Guo XY; Chen YX; Xu YC; Lei YM; Liu KF; Lin DJ; Liu LL; Liu XF
    Mol Med Rep; 2017 Oct; 16(4):4603-4612. PubMed ID: 28849186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
    Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
    Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.
    Beharry Z; Zemskova M; Mahajan S; Zhang F; Ma J; Xia Z; Lilly M; Smith CD; Kraft AS
    Mol Cancer Ther; 2009 Jun; 8(6):1473-83. PubMed ID: 19509254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
    Yang Q; Chen LS; Gandhi V
    Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Pim kinases: new targets for drug development.
    Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
    Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
    Martín-Sánchez E; Odqvist L; Rodríguez-Pinilla SM; Sánchez-Beato M; Roncador G; Domínguez-González B; Blanco-Aparicio C; García Collazo AM; Cantalapiedra EG; Fernández JP; Curiel del Olmo S; Pisonero H; Madureira R; Almaraz C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; Real FX; García JF; Bischoff JR; Piris MA
    PLoS One; 2014; 9(11):e112148. PubMed ID: 25386922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer.
    Liu Z; He W; Gao J; Luo J; Huang X; Gao C
    Oncotarget; 2015 Apr; 6(10):8019-35. PubMed ID: 25749522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting PIM kinase activity significantly augments the efficacy of cytarabine.
    Kelly KR; Espitia CM; Taverna P; Choy G; Padmanabhan S; Nawrocki ST; Giles FJ; Carew JS
    Br J Haematol; 2012 Jan; 156(1):129-32. PubMed ID: 21689092
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.